GEM Pharma has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than four decades working on influencing the production level of protein in the cell to achieve healing via regulation of gene expression without interfering with genetics.
GEM Pharma products cover a wide range of inflammatory conditions, and future developments are expanding the range further. All products are based on Gene Expression Modification and have a solid scientific and clinical base.
VIA mRNA CALIBRATION
GEM Pharma is a pharmaceutical company that develops and brings to market safe, affordable medications for inflammatory conditions based on the unique Gene Expression Modification platform.
GEM Pharma is a spinoff of Resdevco Ltd. a pharmaceutical research company that was established over 40 years ago. The pioneering research was developed by Prof. Shabtay Dikstein (Prof. Emeritus) of the Hebrew University. Recognized by the university and internationally as a creative, groundbreaking inventor and innovator. The strength of GEM Pharma lies not only on the innovative and groundbreaking G.E.M platform but also on the strong network of professionals that has been built over the last three decades.
Our platform is potentially applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify the disease. The depth and versatility of our technologies enable us to address conditions in virtually any therapeutic area.